13 completed, 1 terminated, 1 unknown. 10 Phase 3, 4 Phase 2, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Unknown 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Terminated 1 |
Follow fluticasone-formoterol: new trials by email Literature Review of fluticasone-formoterol trials Research Report on fluticasone-formoterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years Fluticasone/ Formoterol, fluticasone/ salmeterol - Asthma | Phase 3 | Unknown | Mundipharma (China) Pharmaceutical Co. Ltd | 330 | 2017-06-02 | 2019-04-29 |
| Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol Fluticasone/Formoterol, Fluticasone/Salmeterol - Asthma | Phase 4 | Terminated | Mundipharma Korea Ltd | 15 | 2015-08-31 | 2018-05-16 |
| Flutiform® Compared With Seretide® in the Treatment of COPD Flutiform 500/20 µg BID, Flutiform 250/10 µg BID, Seretide Accuhaler 50/500 µg BID - Chronic Obstructive Pulmonary Disease | Phase 2 / Phase 3 | Completed | Mundipharma Research Limited | 923 | 2014-09-01 | 2017-03-28 |
| Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years. Flutiform 50/5 ug (2 puffs bid) pMDI, Fluticasone 50 ug (2puffs bid) pMDI, Beclometasone Autohaler 50 ug (2 puffs bid) - Mild Persistent Asthma | Phase 2 | Completed | Mundipharma Research Limited | 48 | 2014-02-01 | 2018-10-24 |
| A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD Flutiform, Formoterol - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Mundipharma Research Limited | 1767 | 2013-10-01 | 2018-10-24 |
| Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients Flutiform, Seretide, Flixotide - Asthma | Phase 3 | Completed | Mundipharma Research Limited | 498 | 2012-03-01 | 2018-10-24 |
| A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients Formoterol/Fluticasone, Foraseq®, Fluticasone - Asthma | Phase 3 | Completed | Eurofarma Laboratorios S.A. | 222 | 2012-01-01 | 2015-06-18 |
| Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma Flutiform, Symbicort Turbohaler - Asthma | Phase 3 | Completed | Mundipharma Research Limited | 261 | 2010-04-01 | 2018-10-24 |
| Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma fluticasone propionate, formoterol fumarate - Mild to Moderate Asthma | Phase 2 | Completed | SkyePharma AG | 39 | 2008-09-01 | 2010-08-27 |
| A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005 SKP FlutiForm HFA pMDI - Asthma | Phase 3 | Completed | SkyePharma AG | 280 | 2008-09-01 | 2011-06-23 |
| A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg - Asthma | Phase 1 | Completed | SkyePharma AG | 160 | 2008-04-01 | 2008-12-01 |
| An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma Flutiform, Flixotide plus Foradil - Asthma Bronchiale | Phase 3 | Completed | Mundipharma Research Limited | 227 | 2007-09-01 | 2018-10-24 |
| Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma FLUTIFORM® (Formoterol fumarate / Fluticasone propionate) - Asthma Bronchiale | Phase 3 | Completed | Mundipharma Research Limited | 228 | 2007-04-01 | 2018-10-24 |
| Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma FLUTIFORM® (Formoterol fumarate / Fluticasone propionate) - Asthma | Phase 3 | Completed | Mundipharma Research Limited | 211 | 2007-03-01 | 2018-10-24 |
| Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients fluticasone propionate, formoterol fumarate - Asthma | Phase 2 | Completed | SkyePharma AG | 64 | 2004-10-01 | 2011-06-23 |
Asthma (11) · Pulmonary Disease, Chronic Obstructive (2) · Lymphoma, Follicular (1)
Mundipharma Research Limited (8) · SkyePharma AG (4) · Eurofarma Laboratorios S.A. (1) · Mundipharma (China) Pharmaceutical Co. Ltd (1) · Mundipharma Korea Ltd (1)
Romania (6) · Hungary (5) · Poland (5) · United Kingdom (4) · Bulgaria (3) · Germany (3) · Ukraine (3) · United States (3) · China (2) · Czechia (2) · India (2) · Russia (2) · South Korea (2) · Australia (1) · Brazil (1)
Thao T Doan, MD (1) · Victoria Yu (1)
PMID 36472162, PMID 21605396, PMID 23081745, PMID 23368897, PMID 29256049
2009 (1)